Quantro and Boehringer Ingelheim Hit Milestone in Cancer Treatment Development

Quantro Therapeutics, which focuses on transcription factors targeting cancer treatments, announced that it has reached a key milestone in its joint R&D program with Boehringer Ingelheim.

In successfully applying Quantro’s proprietary Quantroseq Transcriptional Fingerprint technology, all pre-set goals for technical proof-of-concept, cross-validation of HTS screening technology, and identification of high-quality hits for a previously undruggable transcription factor were fully accomplished.

Cancer, a leading global cause of death, often has limited treatment options. Transcription factors, key gene expression regulators often disrupted in cancer, are promising therapeutic targets. Despite being hard to target with drugs, the 2022 joint R&D program aims to develop innovative, first-in-class cancer treatments targeting these factors.

Michael Bauer, CEO of Quantro, commented, “We are committed to drive a positive change for people affected by cancer, and to that end are looking forward to developing new mode of action compounds jointly with Boehringer Ingelheim. In reaching this milestone, Quantro Therapeutics continues to advance its leading transcriptomic R&D platform to build a highly innovative pipeline of modulators, inhibitors or degraders of transcription factors, transcriptional regulators and cell signaling targets.“

Quantro and Boehringer Ingelheim reach milestone in collaboration to develop...
Quantro and Boehringer Ingelheim reach milestone in collaboration to develop first-in-class cancer treatments. © Adobe Stock

“We are excited and encouraged to see a very convincing and robust technology proof of concept, and highly attractive hits from the first screening that we can directly take to the next discovery and development stages," said Norbert Kraut, Global Head of Cancer Research at Boehringer Ingelheim. "We look forward to further expanding our pipeline of first-in-class treatments to address the remaining high unmet patient need in cancer in partnership with Quantro.”

Upon accomplishment of this milestone, Quantro will receive an undisclosed milestone payment in addition to previously received upfront payments and R&D funding. The total potential transaction value may exceed €500 million in the form of R&D funding and success-driven discovery, development, regulatory, and commercial milestones.

Company

QUANTRO Therapeutics GmbH

Dr. Bohr-Gasse 7 A
1030 Vienna
Austria

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.